Please login to the form below

Not currently logged in
Email:
Password:

obinutuzumab

This page shows the latest obinutuzumab news and features for those working in and with pharma, biotech and healthcare.

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

This analysis showed that the chemotherapy-free Venclyxto (venetoclax) plus Gazyvaro (obinutuzumab) regimen had an estimated PFS rate of 74% in previously untreated patients with chronic lymphocytic leukaemia (CLL) compared to

Latest news

More from news
Approximately 11 fully matching, plus 31 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...